All In Biotech

Drug Trial Radar · NCT05141994

Clinical Study on the Efficacy and Safety of BAT5906 Injection

Phase II Clinical Study on the Efficacy and Safety of BAT5906 Injection in the Vitreous Age-related Macular Degeneration Patients With Two Repeated Intravitreal Dose

Last checked: Nov 19, 2026Latest source record: Apr 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Aug 26, 2020

Primary completion

Sep 6, 2022

Study completion Sep 6, 2022

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open, and phase II clinical study to evaluate the efficacy and safety of BAT5906 injection in patients with wet age-related macular degeneration. The results of the BAT5906 Phase I study show that it is safe from 0.3-4.0 mg, and that higher doses (2.5 mg and 4 mg) may be substituted for the duration of maintenance efficacy; drugs with the same target (such as brolucizumab and Abecip) have also been found in clinical studies High doses can extend the interval and reduce the frequency of administration. Therefore, in this study, two doses with better safety and efficacy were selected, once every 4 weeks, followed by 3 consecutive injections for treatment as needed, and preliminary exploration of the best clinical effective dose and replacement frequency

Conditions

  • Wet Age-related Macular Degeneration

Interventions

  • 2.5mg of BAT5906Drug

    Specification: 2.5mg of BAT5906

  • 4mg of BAT5906Drug

    Specification: 4mg of BAT5906

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-response relationshipsTime frame: week 24

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Hospital of China Academy of Chinese Medical Sciences

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • Jieyang People's Hospital

    Jieyang, China

  • The First Hospital of Jilin University

    Jilin City, China

  • he Affiliated Eye Hospital of Nanchang University

    Nanchang, China

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong

    Shantou, China

  • West China Hospital of Sichuan University

    Sichuan, China

  • Wenzhou Medical University Affiliated Optometry Hospital

    Wenzhou, China

  • The Second Xiangya Hospital of Central South University

    Xiangya, China

  • Henan Provincial Eye Hospital

    Zhengzhou, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.